SLC5A2 and Schnyder corneal dystrophy: Whereas other meta-analyses by Li et al. and Sfairopoulos et al. showed a reduction in the risk of SCD in diabetic patients with SGLT-2 inhibitors, this reduction was not statistically significant (57, 58).